Home > Online Clinic News > Contrave to Apply for European License

Latest News

by Robert MacKay, Thursday, August 8, 2013 | Categories: Slimming Pills

It is a while since we last reported on Contrave, the experimental weight loss medication concocted by Orexigen Therapeutics from two existing medications: bupropion and naltrexone.  The medication met the FDA’s minimum efficacy requirements for a weight loss medication, even although the results were not staggering. At the end of the day however, the FDA declined to provide a license and asked the company to conduct exhaustive cardiovascular studies, which are now under way.

There really is a dearth of weight loss medications available for us to prescribe for obese or overweight patients, so we are more than happy to hear that the European Medicines Agency has been constructive in its approach to Contrave and Orexigen intends to submit a Marketing Authorization Application in the next few months. The company should have interim results from its cardiovascular study by the time of the 120 day questions from the European Medicines Agency and it seems that these interim results will be acceptable to the agency in terms of taking the application forward.

With Qsiva being rejected by the EMA and Lorcaserin running out of time and being voluntarily withdrawn, let’s hope that Contrave fairs better. You can read more about Contrave here.

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more Close